VacZine Analytics  
MarketVIEW: Zika virus vaccines

Part of MasterVIEW 2020, updated April 2023
Click here>>

Zika virus (ZIKV) is a member of the Flaviviridae family that includes several mosquito-borne viruses of major clinical importance, including yellow fever virus, Japanese encephalitis virus and dengue virus. Although widely distributed across West and East Africa and Southeast Asia (89 countries/territories as of 2021), ZIKV has only recently been identified as a major cause of severe disease since its discovery in the 1940s. The WHO declared the Zika virus outbreak a global emergency in February 2016. In most cases, ZIKV usually causes a mild and often asymptomatic illness. However, neonatal microcephaly (SCZ) and Guillain-Barre syndrome (GBS) are established as severe complications of ZIKV infection. For example, in Brazil, an estimated 200,000 ZIKV (probable + confirmed) cases have persisted since 2017 (after the 2015/16 peak). 3,707 neonatal microcephaly confirmed cases have been reported although many are under investigation (Ministeria de Saude).

ZIKV has the potential to spread to other countries in the PAHO region/ROW that have Aedes mosquitoes. Autochthonous ZIKV transmission (albeit rare) has occured in the US where the Gulf coast region and Florida are most vulnerable regions. Similary, in the EU, autochthonous has occurred in the Var department in France, 2019. Many private sector companies and government-funded organizations are working on developing a Zika vaccine due to the significant global public health concern. Key companies are ModernaTX (mRNA-1893), Takeda Vaccines (TAK-426) and Valneva SE (VLA1601).

This MarketVIEW product is a comprehensive MS Excel-based model + Executive presentation that forecast the potential commercial value of Zika virus vaccines across endemic (public + private), stockpile and travelers markets to 2035. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates for all key commercial segments. LO/BASE/HI forecast scenarios are included based upon a differing pricing justifications. An up to date review is also given for latest disease background and epidemiology, with current R&D status.

THIS PRODUCT IS AN EXECUTIVE PRESENTATION (~150 slides) and 1x MS-Excel FORECAST MODEL image credit: istock images

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV068 Click here>> Single region $8,995
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2023 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains